On 13 November 2026, Huawei officially unveiled the Sense G1 — its first continuous glucose monitor (CGM). The device received a national-level Class III registration certificate (国械注准 20263072228), issued on 30 October 2026. This is the highest category of medical devices in China, on par with cardiac stents and artificial joints.
The Sense G1 is a round sensor roughly the size of a coin or an AirTag that attaches to the skin on the upper arm. Beneath the skin sits a soft needle that uses glucose oxidase and electrodes to measure glucose levels in interstitial fluid. Data is transmitted to Huawei smartphones and compatible smartwatches without calibration, with a lag of 5–15 minutes. A single sensor works for up to 16 days, supports swimming and is intended for a single user.
Accuracy is stated at a MARD below 10%. When glucose levels deviate from the set thresholds, the device sends notifications. The system is aimed at adult patients with diabetes aged 18 and older and allows real-time trend tracking via the app or the watch. Previously, Huawei offered only hyperglycemia risk assessment based on the Watch 4 via pulse wave, without direct glucose measurement.
The price, sales start date and international launch plans have not yet been announced. Class III approval confirms compliance with the regulator's strict requirements for clinical accuracy and safety, but does not guarantee an immediate commercial release. Markets outside China will require separate certification.
Compared with existing CGM systems, the Sense G1 stands out for its integration with the Huawei ecosystem: data is displayed directly on the watch without an additional device. However, the absence of independent MARD tests and precise sensor battery-life specifications leaves open questions about real-world performance in everyday use.
For owners of Huawei Watch and smartphones, the Sense G1 could become a convenient addition to existing health features, if the price proves competitive and the accuracy is confirmed in practice.

